Amnion derived mesenchymal stem cell therapy for spinal cord injury

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K18447
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56010:Neurosurgery-related
• Research Institution: Hyogo Medical University
• Principal Investigator: Kageyama Hiroto 兵庫医科大学, 医学部, 准教授 (60461068)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 脊髄損傷 / 間葉系幹細胞 / 羊膜由来間葉系幹細胞

Outline of Final Research Achievements

A mouse spinal cord injury model was created, and after 3 days of administration of amnion-derived mesenchymal stem cells, the degree of motor and sensory impairment was observed over time. In the chronic phase, gait analysis was performed and walking ability was compared. No significant difference was observed in motor function, but sensory function was improved by cell administration. The gait analysis showed that the patients walked faster, took more steps, and had higher toe position after cell administration, indicating that motor function improved.The findings are relevant to the treatment of future spinal cord injuries.

Free Research Field

脊椎・脊髄疾患の治療

Academic Significance and Societal Importance of the Research Achievements

脊髄損傷への治療は自己骨髄由来間葉系幹細胞であるステミラック注が条件付き承認されたが、これは慢性期治療となる。我々は急性期に抗炎症を目的した他家移植を念頭においた研究を継続しており、より早い時期に投与できる。このことは従来の治療以外の選択肢となりうる社会的意義・ニーズの高い研究であった。その機序として、神経保護因子の増加や炎症抑制が確認されたことは学術的に興味深い結果であった。